According to the UK based company Oxford Biomedica (LSE: OXB), the US FDA has given its approval for the initiation of an open label dose… Read More »UK company reports FDA approval of Phase I/II study for Usher’s syndrome type 1B
Advanced Cell Technology, Inc. (OTCBB: ACTC), a specialized biotechnology company based in Santa Monica, California, has announced receipt of approval from the UK Medicines and… Read More »Advanced Cell Therapeutics receives approval for first human embryonic stem cell trial in the EU
A clinical report on the 3-year follow up data for a gene therapy treatment in patients with Leber’s Congenital Amaurosis (LCA) has concluded the therapy… Read More »3-year follow up data in 15 patients receiving RPE-65 gene therapy treatment for LCA
Clinical research from the University of Catania, Italy has demonstrated a positive benefit to glaucoma patients from the oral administration of PEA (palmitoyl-ethanolamide), a shorter… Read More »Italian clinical study shows potential application of PEA for reducing intraocular pressure (IOP)
Neurotech Pharmacueticals Inc., (Rhode Island, USA) have reported that their intraocular implantable capsule, which delivers ciliary neurotrophic factor (CNTF) to the back of the eye,… Read More »Treatment of retinal degeneration with CNTF shows statistically significant preservation of photorec
Advanced Cell Technologies, Inc (“ACT”, OTCBB: ACTC) of Marlborough, Massachusetts have announced the dosing of the first patients in each of its two Phase I/II… Read More »First patients undergo embryonic stem cell transplantation for Stargardt’s disease and macular degen
Injection of ranibizumab (Lucentis) or bevacizumab (Avastin) are currently the standard treatment for neovascular AMD however, the response to treatment can vary among patients. Advance… Read More »Response to anti-VEGF treatments shown to associate with specific genetic sequences
French medics based at ophthalmic clinics in Paris and Marseille have warned of the long-term retinal toxicity risk associated with the use of “poppers” –… Read More »French clinicians report on foveal damage in users of the recreational drug,
The U.K.’s National Institute for Health & Clinical Excellence (NICE) announced on June 6th that it would be recommending the use of the dexamethasone 0.7g… Read More »NICE in UK recommends Ozurdex for central vein retinal occlusion (CRVO)
In a long-awaited pronouncement from the Comparison of Age-Related Macular Degeneration Treatment Trials (CATT) Research Group, 1 year study results have shown that the monthly… Read More »CATT study demonstrates equivalency between Avastin (bevacizumab) and Lucentis (ranibizumab) at year